Strategies for engineered negligible senescence

Strategies for engineered negligible senescence (SENS) is a range of proposed regenerative medical therapies, either planned or currently in development, for the periodic repair of all age-related damage to human tissue. These therapies have the ultimate aim of maintaining a state of negligible senescence in patients and postponing age-associated disease.[1] SENS was first defined by British biogerontologist Aubrey de Grey. Many mainstream scientists believe that it is a fringe theory.[2] De Grey later highlighted similarities and differences of SENS to subsequent categorization systems of the biology of aging, such as the highly influential Hallmarks of Aging published in 2013.[3][4]

While some biogerontologists support the SENS program, others contend that the ultimate goals of de Grey's programme are too speculative given the current state of technology.[5][6] The 31-member Research Advisory Board of de Grey's SENS Research Foundation have signed an endorsement of the plausibility of the SENS approach.[7]

  1. ^ de Grey, Aubrey; Rae, Michael (September 2007). Ending Aging: The Rejuvenation Breakthroughs that Could Reverse Human Aging in Our Lifetime. New York, NY: St. Martin's Press, 416 pp. ISBN 0-312-36706-6.
  2. ^ Warner, H.; Anderson, J.; Austad, S.; Bergamini, E.; Bredesen, D.; Butler, R.; Carnes, B. A.; Clark, B. F. C.; Cristofalo, V.; Faulkner, J.; Guarente, L.; Harrison, D. E.; Kirkwood, T.; Lithgow, G.; Martin, G.; Masoro, E.; Melov, S.; Miller, R. A.; Olshansky, S. J.; Partridge, L.; Pereira-Smith, O.; Perls, T.; Richardson, A.; Smith, J.; Von Zglinicki, T.; Wang, E.; Wei, J. Y.; Williams, T. F. (Nov 2005). "Science fact and the SENS agenda. What can we reasonably expect from ageing research?". EMBO Reports. 6 (11): 1006–1008. doi:10.1038/sj.embor.7400555. ISSN 1469-221X. PMC 1371037. PMID 16264422.
  3. ^ De Grey, Aubrey D.N.J. (2023). "The Divide-and-Conquer Approach to Delaying Age-Related Functional Decline: Where Are We Now?". Rejuvenation Research. 26 (6): 217–220. doi:10.1089/rej.2023.0057. PMID 37950714. S2CID 265127778.
  4. ^ https://www.cell.com/fulltext/S0092-8674(13)00645-4 [bare URL]
  5. ^ Warner H; Anderson J; Austad S; et al. (November 2005). "Science fact and the SENS agenda. What can we reasonably expect from ageing research?". EMBO Reports. 6 (11): 1006–8. doi:10.1038/sj.embor.7400555. PMC 1371037. PMID 16264422.
  6. ^ Holliday R (April 2009). "The extreme arrogance of anti-aging medicine". Biogerontology. 10 (2): 223–8. doi:10.1007/s10522-008-9170-6. PMID 18726707. S2CID 764136.
  7. ^ "Research Advisory Board". sens.org. Archived from the original on 14 June 2021. Retrieved 15 July 2021.